The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
To evaluate the frequency and clinicopathological features of ROS1 and RET rearrangements in N2 node positive stage IIIA (IIIA-N2) non-small cell lung cancer (NSCLC) patients, we retrospectively screened 204 cases with a tissue microarray (TMA) panel by fluorescent in situ hybridization (FISH), and...
Main Authors: | Sha Fu, Ying Liang, Yong-Bin Lin, Fang Wang, Ma-Yan Huang, Zi-Chen Zhang, Jing Wang, Wen-Jian Cen, Jian-Yong Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4408029?pdf=render |
Similar Items
-
RET rearrangements: targeted therapy in lung cancer
by: Susana Patrícia de Castro Moita
Published: (2021) -
RET gene fusions/rearrangements as biomarkers for lung carcinoma
by: Avinash A Rasalkar, et al.
Published: (2021-01-01) -
Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update
by: Luis Mendoza
Published: (2018-07-01) -
Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer.
by: Bing-Yen Wang, et al.
Published: (2016-01-01) -
Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection
by: Anna Lowczak, et al.
Published: (2020-05-01)